PDF(Pubmed)
Abstract：
BACKGROUND: HIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir + rilpivirine long-acting (CAB + RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection by a healthcare professional (HCP). The objective of this analysis was to assess potential healthcare resource use (HRU) and cost impact of implementing CAB + RPV LA vs. daily oral ART at National Health System (NHS) hospitals.
METHODS: Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2022).
RESULTS: 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART.
CONCLUSIONS: These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving.
METHODS: Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2022).
RESULTS: 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART.
CONCLUSIONS: These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving.
摘要：
背景：HIV治疗目前包括每日口服抗逆转录病毒疗法（ART）。Cabotegravir+rilpivirine长效（CAB+RPVLA）是西班牙第一种由医疗保健专业人员（HCP）通过肌肉注射每2个月进行一次的ART。本分析的目的是评估潜在的医疗保健资源使用(HRU)和成本影响实施CAB+RPVLA与国家卫生系统（NHS）医院每日口服ART。
方法：进行在线定量访谈和成本分析。传染病专家（IDS），医院药剂师（HP）和护士被问及他们对CAB+RPVLA与HRU之间潜在差异的看法日常口腔艺术，在其他兴趣概念中。西班牙官方关税作为单位成本适用于HRU估计（2022欧元）。
结果：120名响应者（n=40IDS，n=40HP,n=40名护士)按专业估计每位患者的平均年度就诊次数(IDS，HP,护士，分别)3.3与3.7;4.4vs.6.2；6.1vs.3.9，适用于CAB+RPVLA与日常口腔艺术，和3.0vs.3.2；4.8vs.5.8；6.9vs.4.9，分别由相应的专家响应进行调整。按总样本估算导致每位患者的年度总费用为2,076欧元，而不是€2,473，为€2,032vs.经过相应的HCP调整后的2,237欧元，CAB+RPVLAvs.日常口腔艺术。
结论：这些结果表明，与目前的日常口服ART相比，在NHS医院实施CAB+RPVLA不会增加HRU相关费用，可能保持中立甚至节省成本。
方法：进行在线定量访谈和成本分析。传染病专家（IDS），医院药剂师（HP）和护士被问及他们对CAB+RPVLA与HRU之间潜在差异的看法日常口腔艺术，在其他兴趣概念中。西班牙官方关税作为单位成本适用于HRU估计（2022欧元）。
结果：120名响应者（n=40IDS，n=40HP,n=40名护士)按专业估计每位患者的平均年度就诊次数(IDS，HP,护士，分别)3.3与3.7;4.4vs.6.2；6.1vs.3.9，适用于CAB+RPVLA与日常口腔艺术，和3.0vs.3.2；4.8vs.5.8；6.9vs.4.9，分别由相应的专家响应进行调整。按总样本估算导致每位患者的年度总费用为2,076欧元，而不是€2,473，为€2,032vs.经过相应的HCP调整后的2,237欧元，CAB+RPVLAvs.日常口腔艺术。
结论：这些结果表明，与目前的日常口服ART相比，在NHS医院实施CAB+RPVLA不会增加HRU相关费用，可能保持中立甚至节省成本。
